Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.50 |
| ▸ | ERN1 | O75460 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.38 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7560387 | 0.88 | ESR1 (0.43) | ESR1ESR2ERN1XDHPTPN1 | |
| SCHEMBL26982053 | 0.83 | ESR1 (0.50) | ESR1ESR2ERN1FFAR4PTPN1 | |
| SCHEMBL6712825 | 0.83 | ESR1 (0.50) | ESR1ESR2HIF1AFFAR4PTPN1 | |
| SCHEMBL6711117 | 0.83 | ESR1 (0.44) | ESR1ESR2ERN1PTPN1AHR | |
| SCHEMBL6711107 | 0.82 | ESR1 (0.50) | ESR1ESR2HIF1AFFAR4XDH | |
| SCHEMBL6712729 | 0.80 | ALDH1A1 (0.40) | ESR1ESR2XDHPTPN1HSP90AA1 | |
| SCHEMBL26982289 | 0.80 | ESR1 (0.47) | ESR1ESR2ERN1HIF1APTPN1 | |
| SCHEMBL27443248 | 0.78 | ESR1 (0.48) | ESR1ESR2ERN1FFAR4PTPN1 | |
| SCHEMBL31256743 | 0.78 | ESR1 (0.54) | ESR1ESR2HIF1AFFAR4KAT6A | |
| SCHEMBL5992116 | 0.76 | ESR1 (0.59) | ESR1ESR2HIF1AFFAR4GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040229910-A1 | Therapeutic compounds | N.V. ORGANON (NL) | 2004-11-18 | — | — | US | disclosed |
| CN-1139580-C | Substituted benzylamines and their use for the treatment of depression | ��˹��ŵ�� | 2004-02-25 | — | — | CN | disclosed |
| EP-0898566-B1 | SUBSTITUTED BENZYLAMINES AND THEIR USE FOR THE TREATMENT OF DEPRESSION | AKZO NOBEL NV (NL) | 2002-11-06 | — | — | EP | disclosed |
| US-20020037885-A1 | Therapeutic compounds | DIJCKS FREDERICUS ANTONIUS (NL) | 2002-03-28 | — | — | US | disclosed |
| US-6313139-B1 | ADMINISTERING BENZYLAMINE DERIVATIVE FOR THERAPY OF PSYCHIATRIC DISORDER IN MAMMALS | AKZO NOBEL N. V. (NL) | 2001-11-06 | — | — | US | disclosed |
| US-6080773-A | USEFUL FOR TREATMENT OF DEPRESSION, ANXIETY OR PSYCHOSIS | AKZO NOBEL, N.V. (NL) | 2000-06-27 | — | — | US | disclosed |
| CN-1219169-A | Substituted benzylamines and their use for the treatment of depression | AKZO NOBEL NV (NL) | 1999-06-09 | — | — | CN | disclosed |
| EP-0898566-A1 | SUBSTITUTED BENZYLAMINES AND THEIR USE FOR THE TREATMENT OF DEPRESSION | Akzo Nobel N.V. (NL) | 1999-03-03 | — | — | EP | disclosed |
| WO-1997040027-A1 | SUBSTITUTED BENZYLAMINES AND THEIR USE FOR THE TREATMENT OF DEPRESSION | AKZO NOBEL N.V. (NL) | 1997-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229910-A1 | Therapeutic compounds | BDNF, PNMT, SLC18A2 | ESR1 2865/4885ESR2 1589/4885ERN1 3739/4885 |
| US-20020037885-A1 | Therapeutic compounds | BDNF, PNMT, SLC18A2 | ESR1 2865/4885ESR2 1589/4885ERN1 3739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.